We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin (TOP)

This study has been terminated.
(Low accrual rate)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00162812
First Posted: September 13, 2005
Last Update Posted: July 18, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Gustave Roussy, Cancer Campus, Grand Paris
Centre Paul Strauss
Centre Hospitalier du Luxembourg
Clinique Louis Cathy - Baudour - Belgium
HIS - Site Etterbeek - Ixelles - Belgium
Clinique Saint Pierre - Ottignies -Belgium
Clinique Ste Elisabeth - Namur - Belgium
University Hospital of Crete
Feculdade de Medicina da Universidade de Sao Paulo - Brasil
Information provided by:
Jules Bordet Institute
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: April 2009
  Estimated Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)